Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics, Servier Partner on Deal for Rx, Companion Dx Development

NEW YORK (GenomeWeb News) – French firms Hybrigenics and Servier today announced a licensing and research deal targeting deubiquitinating enzymes, or DUBs, for various diseases that could result in the development of companion diagnostics.

Under the terms of the deal, Hybrigenics will identify and validate new targets among DUBs for cancer, diseases in neurology, psychiatry, rheumatology, and ophthalmology, as well as diabetes, and cardiovascular illness.

It will also screen potential therapeutic agents "able to modulate" four undisclosed targets that have already been chosen as DUBs of interest. Hybrigenics' work, it said, could lead to the discovery of companion diagnostics, "potentially needed for such therapeutic drugs."

Servier will provide the compounds to be screened, as well as develop the selected compounds, and commercialize any approved drugs.

Hybrigenics will receive an upfront payment and research funding totaling €4 million ($5.5 million). If certain milestones are reached, the company could be eligible for an additional €9.5 million for each target that leads to registration of a new drug and to royalties on sales of companion diagnostic kits, it said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.